Rayner Expands EMV Portfolio with the FDA-Approved RayOne EMV Toric IOL

Sponsored by Rayner

Exceptional rotational stability. Effective cylinder reduction. Accurate outcomes.¹

As cataract surgery continues to evolve, surgeons seek IOL technologies that deliver the quality of vision that patients expect. For those with astigmatism, that means choosing a lens that provides proven stability, as well as consistently predictable outcomes. 

Building on the success of RayOne EMV, Rayner now introduces RayOne EMV Toric to the US, extending its trusted optical design to patients with corneal astigmatism. The lens provides surgeons with a familiar platform that delivers effective cylinder correction and exceptional rotational stability. ¹

Developed in collaboration with Professor Graham Barrett, RayOne EMV and EMV Toric feature a unique non-diffractive optic that utilizes controlled positive spherical aberration for high-quality vision¹, with monofocal levels of contrast sensitivity², low dysphotopsia³ and high patient satisfaction.⁴

“RayOne EMV is a solution that gives patients increased satisfaction with the least compromise in their quality of vision. I am pleased that US surgeons will now have access to the full EMV family of lenses, including a rotationally stable toric option for patients with astigmatism.”
— Professor Graham Barrett, developer of RayOne EMV

Clinical performance supported by FDA data 

Clinical outcomes from a robust FDA IDE trial highlight RayOne EMV Toric’s ability to deliver consistent, predictable results for patients with astigmatism¹:

• At Day 1-2 post-op, RayOne EMV Toric demonstrated an absolute mean rotation of just 0.9°. *
• At Month 6, RayOne EMV Toric showed an absolute lens alignment of only 3.5°**, with at least 99 % of eyes rotating ≤5°, exceeding FDA requirements.***
• RayOne EMV Toric demonstrated a clinically significant reduction in residual cylinder, surpassing the FDA’s recommendation of 0.4 D.
• From Month 1: >85% of eyes were within ±0.50 D of target.

The results confirm that RayOne EMV Toric provides accurate, stable correction for patients undergoing cataract surgery with astigmatism. 

“In my experience, the RayOne EMV Toric performed exceptionally well – delivering excellent outcomes with the added benefit of Rayner’s platform providing outstanding rotational stability. I’m confident this lens will become an important option for patients who want both refractive precision and stability. I’m honored to have played a role in helping bring this innovation to the US, and I’m looking forward to what’s next with Rayner.”
— William Wiley, MD, Cleveland Eye Clinic

With FDA approval of RayOne EMV Toric, surgeons can now correct more of their patients, even those with significant corneal astigmatism – achieving exceptional rotational stability, effective cylinder reduction, and accurate outcomes.¹

Learn more about RayOne EMV Toric at www.rayner.com/EMV 

Attending AAO? Visit Rayner at Booth #2201.

Editor’s Note: The Annual Meeting of the American Academy of Ophthalmology (AAO 2025) is being held 17-20 October in Orlando, Florida, United States. This content is intended exclusively for healthcare professionals. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners.

References

1. Rayner RayOne EMV Toric FDA IDE study (G230072).
2. Ferreira TB. Presented at ESCRS 2022 [Paper]. 
3. Findl O. et al. American Journal of Ophthalmology. 2025; 271:86-95. 
4. RayPRO 2025, data on file.

*Mean absolute axis rotation (difference between IOL axis orientation from end of surgery to post-op Day 1-2). **Mean absolute axis misalignment (difference between intended IOL axis and IOL axis orientation at 6M).
*** Measured between consecutive visits from Day 1 to 6M.